Study of Supersaturated Oxygen Therapy Through Wrist Access to Prevent Heart Damage After Anterior Heart Attack

What this Trial Is About

Researchers are investigating a new approach to treat patients who have had a heart attack, specifically acute anterior ST-segment elevation myocardial infarction STEMI. This condition can cause serious damage to the heart muscle, leading to heart failure and early death. Despite many studies, few new treatments have shown success in preventing heart failure after a heart attack. This trial aims to explore the safety, feasibility, and possible benefits of increasing blood oxygen levels after the usual treatment. The standard treatment involves reopening the blocked heart artery through a procedure called primary percutaneous coronary intervention PCI using access via the wrist. After this, patients are randomly assigned to receive either supersaturated oxygen therapy or a sham procedure for one hour. Supersaturated oxygen therapy uses extra oxygenated blood infused back into the treated artery through the wrist, while the sham group undergoes a similar procedure without the oxygen infusion. Both groups will be monitored under blinded conditions to ensure unbiased results. Participants will undergo various assessments including blood tests, coronary angiography, heart MRI scans at 2-5 days and again at 3 months, and health questionnaires. Coronary microvascular function will be measured before and after the treatment or sham procedure. Follow-up visits will continue for up to one year, with health records monitored longer term. The main outcome measured is a heart-related blood marker at 3 months, along with secondary outcomes including heart function, infarct size, quality of life, and safety events.

Heart Attack Blood Oxygen Therapy Trial